IV iron use in patients with higher serum ferritin: case study on anemia in kidney disease.
Anemia management practices in patients on hemodialysis that incorporate a balanced approach to erythropoiesis-stimulating agent (ESA) and intravenous (IV) iron therapy, use the lowest effective dose of ESA, and provide IV iron therapy in patients with higher serum ferritin levels have become important treatment considerations. This case study, followed by an indepth discussion, addresses these issues and helps to identify safe and effective treatment strategies to assist nurses in improving patient outcomes.
Larson
Kristin
K
Nephrology Associates, Salt Lake City, UT, USA.
D000368:Aged; D018798:Anemia, Iron-Deficiency / Q000188:drug therapy* / Q000209:etiology; D016903:Drug Monitoring; D004359:Drug Therapy, Combination; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D005293:Ferritins / Q000097:blood* / Q000187:drug effects; D005296:Ferrous Compounds / Q000008:administration & dosage*; D006397:Hematinics / Q000008:administration & dosage* / Q000009:adverse effects; D006454:Hemoglobins / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D007262:Infusions, Intravenous; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D024802:Nurse's Role; D017410:Practice Guidelines as Topic; D011994:Recombinant Proteins; D006435:Renal Dialysis / Q000451:nursing; D012449:Safety; D016896:Treatment Outcome
D005296:Ferrous Compounds; D006397:Hematinics; D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa; D005293:Ferritins